What is the promoter shareholding of Sun Pharma Advanced Research?

The promoters of Sun Pharma Advanced Research currently hold 65.67% of the company’s total shares.

What is the FII and DII shareholding of Sun Pharma Advanced Research?

Foreign Institutional Investors (FIIs) own 2.04%. Domestic Institutional Investors (DIIs) hold 0.03% of Sun Pharma Advanced Research.

What is the retail shareholding of Sun Pharma Advanced Research?

The retail shareholding of Sun Pharma Advanced Research is 31.51%

How often is the shareholding pattern of Sun Pharma Advanced Research updated?

The shareholding pattern of Sun Pharma Advanced Research is updated quarterly as per SEBI regulations.

Sun Pharma Advanced Research Shareholding Pattern

Category	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Promoters	65.67%	65.67%	65.67%	65.67%
Foreign institutions-FII	2.04%	1.76%	1.47%	1.45%
Other domestic institutions	0.03%	0.03%	0.03%	0.12%
Retail and other	31.51%	31.52%	31.88%	31.75%
Mutual Funds	0.76%	1.01%	0.94%	1.01%

Attention Investors & Disclaimer

Upstox Securities Pvt. Ltd.: SEBI Registration No. INZ000315837 | NSE TM Code: 13942 | BSE TM Code: 6155 | MCX TM Code: 46510 | CDSL Reg No.: IN-DP-761-2024 | CIN: U65100DL2021PTC376860 | Compliance Officer: Mr. Kapil Jaikalyani. Tel No.: (022) 24229920. Email ID: compliance@upstox.com | Registered Address: 809, New Delhi House, Barakhamba Road, Connaught Place, New Delhi - 110001 | Correspondence Address: 30th Floor, Sunshine Tower, Senapati Bapat Marg, Dadar (West), Mumbai - 400013. | For any complaints, email at complaints@upstox.com and complaints.mcx@upstox.com.

About the Company

Upstox Securities Private Limited is a wholly owned subsidiary of RKSV Securities India Private Limited.

SEBI Scores

Procedure to file a complaint on SEBI SCORES: Register on the SCORES portal. Mandatory details for filing complaints on SCORES include: Name, PAN, Address, Mobile Number, and E-mail ID. Benefits include effective communication and speedy redressal of grievances. Please ensure you carefully read the Risk Disclosure Document as prescribed by SEBI, along with our Terms of Use and Privacy Policy.

Attention to Investors

Smart Online Dispute Resolution: SEBI has established an Online Dispute Resolution Portal (ODR Portal) for resolving disputes in the Indian Securities Market. This circular streamlines the existing dispute resolution mechanism, offering online conciliation and arbitration, benefiting investors and listed companies.

Collateral: Clearing Corporation has provided a web based facility that allows clients to view their disaggregated collateral placed. Please access them via these links NCL | ICCL

Kindly refer to the Advisory Guidelines issued by Exchanges for trading

Investment Disclaimer

Disclaimer: Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

*Brokerage will not exceed the SEBI prescribed limit and Annual Maintenance charges are free upto one year for users onboarded from 14-Feb-2025 onwards

We do not authorize any person or organization to conduct trades on behalf of Upstox customers. If you find anyone claiming to be part of Upstox or RKSV or representing Upstox/RKSV and offering such services, please send us an email at complaints@upstox.com

Use of New Validated UPI Handles in the Securities Market | CDSL voting on motions moved by Listed Companies

Insurance

RKSV Securities India Pvt. Ltd. ("Upstox") with registered office at 807, New Delhi House Barakhamba Road Connaught Place, New Delhi, Delhi-110001, Delhi (CIN: U74900DL2009PTC189166) is a Corporate Agent registered with Insurance Regulatory and Development Authority of India (IRDAI) (Category: Composite, IRDAI Regn No.-: CA0918 valid till 05-03-2027).

Disclosures/Disclaimers for Insurance Products

Email ID: insurancesupport@rksv.in

Bima Bharosa Portal: https://bimabharosa.irdai.gov.in/

IRDAI: https://irdai.gov.in/

Insurance Ombudsman: https://www.cioins.co.in/